Dilated Cardiomyopathy



aortic valve pulmonary valve :: Article Creator

Anthony Pangilinan Recovering From Heart Surgery; Maricel Laxa Says They Kept It Private 'so We Could Heal Properly'

Published October 17, 2024 1:24pm

Anthony Pangilinan is now recovering following a successful open-heart surgery due to a "mitral heart valve issue."

In an Instagram Reel, the husband of actress Maricel Laxa said that he dug up medical checkup results from months back after experiencing shortness of breath.

Upon showing the results to his neighbor, who is a cardiologist, he was asked to do further tests.

"Long story short, I had a mitral heart valve issue that had a, and I quote, 'torrentially severe leak' and if not for a strong heart, which I think I got from running, I should've already shown more serious heartfelt symptoms," he said in the video.

According to the Mayo Clinic, heart valve disease occurs when one or more of the heart's valves does not work properly.

The heart has four valves: the aortic valve, mitral valve, pulmonary valve, and tricuspid valve, all of which function to ensure that blood flows in the right direction. The mitral valve is located between the upper left and lower left heart chambers.

Leakage in a heart valve occurs when a valve does not close properly or fully, which causes blood to leak backward. The most common type of heart valve disease, per the Mayo Clinic, is mitral valve regurgitation. Symptoms of heart valve disease include shortness of breath, fatigue, chest pain, dizziness, fainting, irregular heartbeat, and swelling of the ankles and feet.

In Anthony's case, he had his heart valve repaired through surgery, which was performed by Dr. Nelson Lee of the Philippine Heart Center.

"With the help of dear friends and family, we prepped for the open-heart surgery with whatever hope and faith we could hold on to," he said.

He added that what should have been a three to five hour surgical procedure turned to 12 hours due to difficulty in inserting the right tube into his lungs.

What was also supposed to be just a week-long stay in the hospital turned into three weeks.

"As a combination of post-operation procedures to clear my lungs, to regular my heart rate, blood pressure, and to initiate my rehabilitation protocols demanded some attention," he said of his extended stay.

Anthony has a long, slow road to recovery ahead of him, sharing that a doctor told him what he experienced was akin to being beaten up by 10 men and hit by 10 trucks.

"To hell and back, I describe it. Whatever way, I made it through by His grace and by the continuing acts of bold faith He equips me, my family, to do daily as I now prepare for the next new season of my life."

Meanwhile, wife Maricel shared in her guesting on Tuesday's "Fast Talk with Boy Abunda" that it has been two weeks since Anthony was discharged from the hospital.

Per the "Lilet Matias: Attorney-at-Law" actress, they did not want to make his heart surgery public so they could heal as a family.

"We just wanted a private time para sa pamilya, so that we could heal properly, all of us, kasi pag dumadaan sa ganitong challenge sa buhay kailangan ng suporta ng bawat isa. And so we went through it quietly and it's the most beautiful thing to go through together," she said.

She also told Tito Boy that her husband has been walking as he heals and has even been back to work.

Maricel and Anthony have five children: Ella, Donny, Hannah, Benj, and Solana.

— CDC, GMA Integrated News


Combined Valve Implantation Improves Severe Emphysema Outcomes

Photo Credit: Mohammed Haneefa Nizamudeen

Combining Zephyr and Spiration valve therapy benefited patients with COPD and advanced pulmonary emphysema while imparting a manageable risk profile.

Endoscopic lung volume reduction using valves represents a minimally invasive approach for managing severe pulmonary emphysema. Among the available options, the Zephyr and Spiration valves are two distinct systems that can be implanted concurrently within the same procedure.

In a study published in Respiratory Medicine, A. Susanne Dittrich, MD, and colleagues aimed to evaluate the impact of combined valve therapy on lung function, exercise capacity, and patient-reported outcomes for people with severe emphysema undergoing endoscopic lung volume reduction.

"Previous studies focused on the outcome of either Zephyr or Spiration valve treatment, but little is known about a combined implantation of Zephyr and Spiration valves during the same bronchoscopic procedure," Dr. Dittrich and colleagues explained.

The researchers performed a retrospective analysis of 108 patients with chronic obstructive pulmonary disease (COPD) who underwent simultaneous implantation of Zephyr and Spiration valves. Clinicians tailored the selection and number of valves implanted to each patient's anatomical requirements. The study authors assessed the effects of the combined treatment on lung function, exercise capacity, and atelectasis formation, along with any associated complications, at 90 and 180 days post-treatment.

At the 90-day follow-up (n=90), the mean change in forced expiratory volume in 1 second (FEV1) was 86.7 ±183.7 mL, and residual volume (RV) showed a mean reduction of -645.3 ±1276.5 mL, with responder rates of 39.8% and 46.5%, respectively. The researchers observed complete atelectasis in 16.7% of patients, while partial atelectasis occurred in 25.5%.

Patients' 6-minute walk tests increased by an average of 27.0 meters (range, -1.5-68.5). The incidence of pneumothorax at 6 months was 10.2%, aligning with rates reported in randomized controlled trials. However, due to the inclusion of high-risk patients in this cohort, there was a notably higher incidence of severe COPD exacerbations (21.3%) and pneumonia (12.0%) compared with other studies.

The researchers concluded that the simultaneous implantation of Zephyr and Spiration valves yielded significant clinical and functional outcomes improvements, with a manageable risk profile.

"The current data show that simultaneous, combined implantation of Zephyr and Spiration valves can be an effective and safe treatment strategy for endoscopic lung volume reduction in patients with severe emphysema and complete interlobar fissures, especially if the anatomy requires it," Dr. Dittrich and colleagues concluded.


Gradient Denervation Technologies Appoints Stanton Rowe To Board Of Directors And Receives FDA Approval To Expand Early Feasibility Study

PARIS, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive, ultrasound-based catheter system designed to treat pulmonary hypertension patients with associated heart failure, announced today that it has appointed medical device serial entrepreneur and executive Stanton Rowe to its board of directors.

Rowe has developed multiple innovative medical technologies through his current incubator, Nidus Biomedical, and with his prior incubator, NXT Biomedical. He served as Chief Scientific Officer of Edwards Lifesciences and was co-founder and CEO of Percutaneous Valve Technologies, the developer of the first transcatheter aortic valve replacement device which was later acquired by Edwards.

Gradient also announced that the Food and Drug Administration (FDA) has approved the expansion of the PreVail-PH2 Early Feasibility Study based on the results from the initial cohort. The study is actively enrolling patients with WHO Group 2 Pulmonary Hypertension at centers in the United States and is recruiting additional clinical centers with heart failure and pulmonary hypertension expertise.

"I'm very excited to join Gradient and work with the company to bring this technology to patients," says Rowe. "Gradient's early experience with pulmonary denervation is promising and I see great potential for this system to provide a new treatment option for these underserved patients."

Stanton Rowe

"Gradient is at a critical point in our development as we build our clinical experience with our ultrasound-based pulmonary artery denervation technology," says Martin Grasse, Gradient's CEO. "I'm delighted to have Stan joining us and am looking forward to leveraging his deep experience to help guide the company in our next phase."

About Gradient Denervation Technologies

Gradient Denervation Technologies is developing a minimally invasive device for the treatment of pulmonary hypertension in patients with heart failure. Gradient leverages intellectual property developed at Stanford University. The Gradient device is for investigational use only and is not approved for commercial use anywhere in the world.

For more information, please visit: https://www.Gradientdenervation.Com.

A photo accompanying this announcement is available at https://www.Globenewswire.Com/NewsRoom/AttachmentNg/84656961-228a-4b69-9c87-378c86d7b88d

image

Primary Logo





Comments

Post a Comment

Popular posts from this blog

poliomyelitis treatment

Image
poliomyelitis treatment Drug and Device News March 2019 - P&T Community Posted: 04 Mar 2019 10:35 AM PST NEW DRUG APPROVALS Ontruzant, a Herceptin Biosimilar The FDA has approved trastuzumabdttb (Ontruzant, Samsung Bioepis Company, Ltd.) for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Trastuzumabdttb, a HER2/neu receptor antagonist, is the third FDA-approved biosimilar of Herceptin (Genentech). Patients should be selected for therapy based on an FDA-approved companion diagnostic. Trastuzumab-dttb carries a boxed warning about the risks of cardiomyopathy, serious and fatal infusion reactions, embryo-fetal toxicity, and pulmonary toxicity. Ontruzant will be marketed and distributed in the U.S. by Merck. Sources: Samsung Bioepis, January 21, 2019; Ontruzant . prescribing information, January 2019; FDA, January 18, 2019 Vaxelis, a Combination Vaccine T
Read more

Co-authors of Minnesota State Fair history book optimistic for event's return - KSTP

Image
Co-authors of Minnesota State Fair history book optimistic for event's return - KSTP Co-authors of Minnesota State Fair history book optimistic for event's return - KSTP Posted: 02 May 2021 05:03 PM PDT "I do remember the polio pandemic. I was 8 years old at the time that that fair was canceled," Kathryn Koutsky said. "And my parents and I, we always went to the fair, and so that really affected me." And last year's modified drive-thru fair looked nothing like what's seen in the history books.  "The fair is so crowded that you just couldn't imagine going into the crowd. I mean, it was awfully sad," said Kathryn's daughter, Linda. "I loved going to the fair. I go several days each year, but you just knew there was no way we could go." But there is some hope for the state fair this year. On Friday, Gov. Tim Walz indicated Minnesota is on track for its retu
Read more

Polio was nearly extinct. Then the anti-vaxx movement reached Pakistan - Los Angeles Times

Image
Polio was nearly extinct. Then the anti-vaxx movement reached Pakistan - Los Angeles Times Polio was nearly extinct. Then the anti-vaxx movement reached Pakistan - Los Angeles Times Posted: 05 Sep 2019 12:00 AM PDT An anti-vaccination movement rooted in suspicions of modern medicine. Unsubstantiated rumors fueled by social media. Children infected with a disease that had been all but wiped out. Polio is making a troubling comeback in Pakistan, and it is being driven by some of the same forces spreading measles in the United States . Two years after health officials declared they were on the verge of eradicating the crippling childhood disease from Pakistan, one of the last countries where it remains endemic, at least 58 children here have tested positive for the virus since January. That is nearly five times the total of all of last year, and the most in a calendar year since 2014 — a major setback for a $1-billion-a-year global eradicat
Read more